FOR IMMEDIATE RELEASE Vancouver, BC — June 16, 2025 — Andira Pharmaceuticals Inc., a therapeutics company developing synergistic, cannabinoid-based treatments for oncology and infectious disease, today announced the successful completion of pre-clinical efficacy studies for AND-259, a first-in-class transdermal cannabinoid treatment for ductal carcinoma in situ (DCIS)—a highly prevalent, early-stage form of breast cancer

FOR IMMEDIATE RELEASE Vancouver, BC, Canada – March 19, 2025 – Andira Pharmaceuticals is pleased to announce the successful completion of a panel of pre-clinical safety studies as a steppingstone toward clinical trials for advanced wound care with medical device candidate SilvanexTM Flex. These standard pre-clinical studies produced positive outcomes,